{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.10","upperLimit":"36.10","value":"20.10"},{"groupId":"OG002","lowerLimit":"13.10","upperLimit":"43.10","value":"30.30"},{"groupId":"OG003","lowerLimit":"54.75","upperLimit":"121.6","value":"62.75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Duration of Response (DOR) was defined as the time from first partial response (PR) or complete response (CR) to the first documentation of progressive disease (PD) or death.\n\nPR:\n\n* \\>= 50% reduction in serum M-protein.\n* Reduction in 24-hour urinary M-protein by \\>= 90% or to less than 200 mg per 24 hours.\n* For non-secretory myeloma, a reduction of \\>= 50% in size of soft tissue plasmacytomas.\n\nCR:\n\n* Negative immunofixation on the serum and urine.\n* Disappearance of any soft tissue plasmacytomas.\n* \\< 5% plasma cells in the bone marrow.\n\nPD:\n\n* Increase of 25% or more from nadir in serum M-protein, absolute increase of \\>= 0.5 g/dL.\n* Increase of 25% or more from nadir in 24-hour urinary M-protein, absolute increase of \\>=200 mg/24 hours.\n* Increase of 25% or more in the percentage of bone marrow plasma cells, absolute increase of \\>=10%.\n\nCalculated using Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Phase 1b - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG001","title":"Phase 1b - ACY-1215 Dose Level 3"},{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG002","title":"Phase 2 - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG003","title":"Phase 2 - ACY-1215 Dose Level 3"}],"paramType":"MEDIAN","populationDescription":"All treated participants in the Efficacy Evaluable population with a best response of PR or CR.","reportingStatus":"POSTED","timeFrame":"From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Weeks"}